Trials / Completed
CompletedNCT04826159
IMPROVE-DiCE: Study to Evaluate Effect of IMB-1018972 on Cardiac Energetics in T2DM & Obesity (Pt 1) With HFpEF (Pt 2)
A Pharmacodynamic Study to Evaluate the Effects of IMB-1018972 on Myocardial Energetics, Metabolism, and Function in Patients With Type 2 Diabetes.
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 49 (actual)
- Sponsor
- Imbria Pharmaceuticals, Inc. · Industry
- Sex
- All
- Age
- 18 Years – 80 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to assess the activity of IMB-1018972 on cardiac energetic reserve at rest and during stress and to assess safety and tolerability
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | IMB-1018972 | Modified release tablet for oral administration |
Timeline
- Start date
- 2021-04-21
- Primary completion
- 2024-08-06
- Completion
- 2024-08-06
- First posted
- 2021-04-01
- Last updated
- 2025-06-29
Locations
1 site across 1 country: United Kingdom
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT04826159. Inclusion in this directory is not an endorsement.